Ignite Creation Date:
2025-12-24 @ 3:52 PM
Ignite Modification Date:
2026-01-25 @ 7:16 PM
Study NCT ID:
NCT02417792
Status:
COMPLETED
Last Update Posted:
2019-09-25
First Post:
2015-04-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Association Between Psoriasis and Intestinal Bacterial Population
Sponsor:
Assuta Hospital Systems
Organization:
Study Overview
Official Title:
The Association Between Psoriasis and Intestinal Bacterial Population
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PIB
Brief Summary:
At least 20 psoriasis patients will be compared to at least 20 participants without psoriasis Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.
Detailed Description:
Intestinal bacterial population has a significant influence on health and sickness conditions. It affects the development and the function of the immune system (Th2, Th1 or Th17) by bacterial protein expression and by the composition of the bacterial population.
Psoriasis is an immune related dermal disease. The trigger for this disease is currently unknown but, it is possible that intestinal bacteria are a factor in its development.
Study design:
Participants will be divided into 3 groups:
* Psoriasis patients treated with topical medications
* Psoriasis patients treated with IV or sub-cutaneous medications (e.g biological medications)
* Healthy participants (control group) Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.
Psoriasis is an immune related dermal disease. The trigger for this disease is currently unknown but, it is possible that intestinal bacteria are a factor in its development.
Study design:
Participants will be divided into 3 groups:
* Psoriasis patients treated with topical medications
* Psoriasis patients treated with IV or sub-cutaneous medications (e.g biological medications)
* Healthy participants (control group) Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: